Wockhardt shares rallied more than 10% in early trade on May 5, 2026, after the pharmaceutical company reported a sharp turnaround in its March quarter (Q4FY26) earnings.
The company posted a 29.9% year-on-year (YoY) rise in revenue, which stood at ₹965 crore compared to ₹743 crore in the same quarter last year. The growth was supported by improved traction across key business segments and better product mix.
Operational performance saw a significant improvement during the quarter. EBITDA jumped to ₹225 crore from ₹64 crore a year ago, indicating strong cost control and operating leverage. As a result, EBITDA margin expanded sharply to 23.3%, compared to just 8.6% in Q4FY25.
Wockhardt also reported a net profit of ₹166 crore, marking a strong turnaround from a net loss of ₹25 crore in the corresponding quarter last year. The return to profitability highlights improved efficiency and stabilisation in core operations.
Disclaimer: This article is generated for informational purposes only and does not constitute financial, investment, or trading advice. The data and analysis presented are based on publicly available market information at the time of writing. Markets are subject to risk. Please consult a qualified financial advisor before making any investment or trading decisions. Business Upturn does not accept responsibility for any losses arising from reliance on this content.